医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Premier Biomedical, Inc. Engages Agent in India to Identify Suitable Joint Venture Partners in Asia

2016年03月09日 AM12:00
このエントリーをはてなブックマークに追加


 

EL PASO, Texas

Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, announced that they have engaged the services of an agent in India. The agent will act in Premier’s interests in locating and securing financing and suitable joint venture partners in India and Asia for the purposes of testing, registering and marketing medications and devices being developed by Premier for the treatment of various diseases, such as fibromyalgia, MS, and cancer.

William A. Hartman, President and CEO of Premier Biomedical, stated, “We believe there are significant advantages in seeking a joint venture with an Indian partner, and see this as the first step to expanding into the entire Asian market through such a mutually beneficial arrangement. While we continue our JV negotiations in Brazil, we believe it is in our best interests to also engage in the pursuit of a similar joint venture arrangement in Asia, which represents about half of the world’s population.”

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” http://www.premierbiomedical.com/

Safe Harbor Notice

Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005620/en/

CONTACT

Premier Biomedical, Inc.
William A. Hartman, 724-633-7033
President
and CEO
PR@premierbiomedical.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Nike Announces Results of the Active Schools Innovation Award in China to Fuel the Culture of Sport and Play for Chinese Youth
  • Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States
  • ニューランド・ラボラトリーズがプロセスエンジニアリング専用ラボを公開
  • 美泰上市全球最先进的人参补剂
  • SpinalCyteが新たな日本国特許を取得